2025-522336-14-00Not yet recruitingPhase 1
A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 26 Sept 2025
- Start date
- 1 Oct 2026
- Lead sponsor
- Bayer AG
- EU CT number
- 2025-522336-14-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 36
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Berlin GmbH | Berlin | Germany | Not yet recruiting |
| CRS Clinical Research Services Mannheim GmbH | Mannheim | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.